Clinical trials: Severe Alopecia Areata
Alopecia Areata
Pilot Study to Evaluate the Efficacy of Ruxolitinib in Alopecia Areata
Alopecia areata (AA) is a common disease of the immune system, known as an "autoimmune" disease. In the disease, the immune system mistakenly destroys the hair follicle, causing hair to fall out.
- Trial name
- NCT01950780
- Testing
- Ruxolitinib
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Columbia University
Alopecia Areata, Alopecia Totalis (AT)
Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA)
This study will compare two oral medicines-tofacitinib and methotrexate-for treating severe alopecia areata, including alopecia totalis (loss of all scalp hair) and alopecia universalis (loss of scalp and body hair).
- Conditions
- Alopecia Areata, Alopecia Totalis (AT), Alopecia Universalis
- Trial name
- TOFA-MTX-AA (NCT07406204)
- Testing
- Tofacitinib, Methotrexate
- Volunteers
- 78 people
- Sponsor
- Hayat Abad Medical Complex, Peshawar
Alopecia Areata
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03898479
- Testing
- CTP-543
- Where
- 91 sites in United States, Canada
- Volunteers
- 1,000 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Alopecia Areata
Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia Areata
This study will evaluate the efficacy and tolerability of once-daily versus twice-daily dosing of CTP-543, in adult patients with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03811912
- Testing
- CTP-543
- Where
- 10 sites in United States
- Volunteers
- 57 people
- Sponsor
- Concert Pharmaceuticals
Hirsutism, Androgenetic Alopecia
DUS on the Prescribing Indications for CPA/EE in 5 European Countries
This study was designed to compile the reasons and specific indications for the prescription of Cyproterone Acetate combined with Ethinyl Estradiol by Health Care Providers.
- Conditions
- Hirsutism, Androgenetic Alopecia, Severe Anemia, Seborrhea
- Trial name
- NCT02494297
- Where
- Germany
- Volunteers
- 1,597 people, healthy volunteers welcome
- Sponsor
- Center for Epidemiology and Health Research, Germany
Alopecia Areata
Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata
This study will evaluate the safety and efficacy of CTP-543 on hair loss in adults with chronic, moderate to severe alopecia areata.
- Trial name
- NCT03137381
- Testing
- CTP-543
- Where
- 13 sites in United States
- Volunteers
- 149 people
- Sponsor
- Concert Pharmaceuticals
Alopecia Areata
A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age
The purpose of the study is to evaluate the pharmacokinetics (how the medicine is changed and eliminated from your body after you take it) and pharmacodynamics (effects of the medicine in the body) of the study medicine (called…
- Trial name
- NCT05650333
- Testing
- Ritlecitinib 20 mg
- Where
- 9 sites in United States
- Volunteers
- 15 people
- Sponsor
- Pfizer
Alopecia Areata
Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata
The purpose of this study is to assess the preliminary efficacy, safety, tolerability, PK, and PD of Daxdilimab in participants with moderate to severe AA, with ≥50% and ≤95% total scalp hair loss as defined by the SALT score at…
- Trial name
- NCT05368103
- Testing
- Daxdilimab
- Where
- 13 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Amgen
Alopecia Areata
Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
This is a multi-center Phase 3 study to evaluate the safety and effectiveness of an investigational study drug (called Jaktinib) in adults (≥18 years and <65 years) who have 50% or greater scalp hair loss.
- Trial name
- AA (NCT05051761)
- Testing
- Jaktinib
- Where
- 2 sites in China
- Volunteers
- 425 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Alopecia Areata
Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)
This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.
- Trial name
- THRIVE-AA2 (NCT04797650)
- Testing
- CTP-543
- Where
- 63 sites in United States, Canada and 5 more
- Volunteers
- 517 people
- Sponsor
- Concert Pharmaceuticals
Alopecia Areata
Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata
This was an open-label, Multi-center, randomized phase Ⅱ study. Patients with severe Alopecia Areata were randomized to receive 50mg bid, 150mg qd or 200 mg qd of oral Jaktinib Hydrochloride Tablets.
- Trial name
- NCT04034134
- Testing
- Jaktinib Hydrochloride Tablets
- Where
- 2 sites in China
- Volunteers
- 111 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Alopecia Areata, Pediatric Disorder
Efficacy and Safety of LH-8 in Paediatric Alopecia Areata
Double-blind, randomised, multi-centre study to evaluate the efficacy and safety of LH-8 cutaneous solution versus placebo in children and adolescents with moderate to severe scalp alopecia areata.
- Trial name
- AA (NCT03240627)
- Testing
- LH-8
- Where
- 3 sites in Bulgaria, France and 1 more
- Volunteers
- 107 people
- Sponsor
- Legacy Healthcare SA
Alopecia Areata
Extension Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata
This study (Unique Protocol ID: ZGJAK020) as an extension of the ongoing "Study to Evaluate Safety and Efficacy of Jaktinib in Adults With Alopecia Areata (Unique Protocol ID:ZGJAK020)" study.
- Trial name
- AA (NCT05255237)
- Testing
- Jaktinib
- Where
- China
- Volunteers
- 315 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Obesity & Overweight, Hair Loss
Scalp Hair Metabolomics in Severe Obesity
The purpose of this research study is to investigate how body weight and weight-loss surgery affect the natural chemicals found in scalp hair over time.
- Conditions
- Obesity & Overweight, Hair Loss, Metabolomics, Bariatric Surgery
- Trial name
- NCT07368842
- Where
- Singapore
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Singapore General Hospital
Alopecia Areata
Retinol Binding Protein 4 Protein in Alopecia Areata Treated With Barcitinib
Assess serum and tissue retinol binding protein 4 in patients with severe alopecia areata in correlation with healthy individuals .
- Trial name
- NCT06545110
- Testing
- Baricitinib Oral Tablet
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- South Valley University
Severe Alopecia Areata
A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia Areata
Alopecia areata (AA) is a disease that happens when the immune system attacks hair follicles and causes hair loss. AA usually affects the scalp and face, but hair loss can happen on any hair-bearing part of the body.
- Trial name
- NCT07772492
- Testing
- Upadacitinib
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 300 people
- Sponsor
- AbbVie
Alopecia Areata
Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata
Alopecia areata (AA) is a medical condition, in which the hair falls out in patches. The hair can fall out on the scalp or elsewhere on the face and body.
- Trial name
- NCT02684123
- Testing
- Apremilast
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Alopecia Totalis, Alopecia Universalis
Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata
Systemic Pulse Glucocorticoids have been shown to be effective in widespread Alopecia areata but not the totalis, universalis or ophiasic type.
- Conditions
- Alopecia Totalis, Alopecia Universalis, Ophiasic Alopecia
- Trial name
- NCT01167946
- Testing
- methylprednisolone sodium succinate
- Where
- Saudi Arabia
- Volunteers
- 42 people
- Sponsor
- King Saud University
Alopecia Areata
Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata
This is a Phase 2a, randomized, double blind, parallel group, multicenter study with an extension period. The study will have a maximum duration of approximately 113 weeks.
- Trial name
- NCT02974868
- Testing
- PF-06651600, PF-06700841
- Where
- 55 sites in United States, Australia and 1 more
- Volunteers
- 142 people
- Sponsor
- Pfizer
COVID-19, SARS-CoV2
Anti-Androgen Treatment for COVID-19
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Conditions
- COVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate Cancer
- Trial name
- NCT04446429
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Volunteers
- 268 people
- Sponsor
- Applied Biology, Inc.